XiaobingYang GuangzhouChina

Xiaobing Yang, M.D., a Chinese nephrologist, vice director of Renal Division, Nanfang Hospital, Southern Medicl University. Main research area is clinical study and trial in AKI and CKD

Wcn26 Post edited Speaker Card

29 March 2026

Time	Session

14:10 15:10	HIT! High Impact Clinical Trials 3 In IgA Nephropathy HeatherReich Moderator heather.reich@uhn.caCanada Sydney Tang Moderator Hong Kong, China YusukeSuzuki Moderator Japan Opening & Introduction Sydney Tang Speaker Hong Kong, China Efficacy and Safety Results of Atrasentan in Patients With IgA Nephropathy on Sodium‚ äìglucose Co-transporter 2 Inhibitors: Phase II, Randomized, Placebo-controlled, Crossover Trial (Assist) HiddoLambers Heerspink Speaker h.j.lambers.heerspink@umcg.nlNetherlands Q&A Efficacy and Safety of a Targeted-release Formulation of Budesonide (HR19042 Capsules) in Patients With Primary IgA Nephropathy: A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 2/3 Trial XiaobingYang Speaker China Q&A Efficacy and Safety of Iptacopan in Patients With IgA Nephropathy (IgAN): Final 24-month Results From the Phase III APPLAUSE-IgAN Study VladoPerkovic Speaker Australia Q&A Closing Remarks Main Hall

Time

Session

14:10

15:10

HIT! High Impact Clinical Trials 3

In IgA Nephropathy

HeatherReich Moderator heather.reich@uhn.caCanada

Sydney Tang Moderator Hong Kong, China

YusukeSuzuki Moderator Japan

Opening & Introduction

Sydney Tang Speaker Hong Kong, China
Efficacy and Safety Results of Atrasentan in Patients With IgA Nephropathy on Sodium‚ äìglucose Co-transporter 2 Inhibitors: Phase II, Randomized, Placebo-controlled, Crossover Trial (Assist)

HiddoLambers Heerspink Speaker h.j.lambers.heerspink@umcg.nlNetherlands
Q&A
Efficacy and Safety of a Targeted-release Formulation of Budesonide (HR19042 Capsules) in Patients With Primary IgA Nephropathy: A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 2/3 Trial

XiaobingYang Speaker China
Q&A
Efficacy and Safety of Iptacopan in Patients With IgA Nephropathy (IgAN): Final 24-month Results From the Phase III APPLAUSE-IgAN Study

VladoPerkovic Speaker Australia
Q&A
Closing Remarks

Main Hall